Cancer immunotherapy development company Marengo Therapeutics appointed Kevin Chin, MD, its chief medical officer.
Dr. Chin, an oncology specialist, most recently served as senior vice president and head of clinical development at 2Seventy Bio, a biotechnology company, according to a March 1 news release from Marengo.
In his new role, Dr. Chin will manage the development of the company's clinical portfolio, the release said.